Literature DB >> 12757887

Immunohistochemical study on the distribution of alpha-synuclein in the central nervous system of transgenic mice expressing a human Cu/Zn superoxide dismutase mutation.

Yoon Hee Chung1, Kyeung Min Joo, Myeung Ju Kim, Choong Ik Cha.   

Abstract

We used the SOD1(G93A) transgenic mice as an in vivo model of amyotrophic lateral sclerosis (ALS) and performed immunohistochemical studies to investigate whether alpha-synuclein is involved in the pathogenesis of ALS. In the spinal cord of transgenic mice, immunohistochemistry showed intense staining of alpha-synuclein mainly in the anterior horn. In the hippocampus of transgenic mice, differential increases in the staining density of alpha-synuclein were observed. In the cerebellar cortex of transgenic mice, the prominent immunostaining of alpha-synuclein was found in the molecular and granular layers. The present study provides the first in vivo evidence that alpha-synuclein immunoreactivity was increased in the central nervous system of SOD(G93A) transgenic mice, suggesting that alpha-synuclein might play an important role in the pathogenesis of ALS. However, the functional implications of these increases require elucidation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12757887     DOI: 10.1016/s0304-3940(03)00237-4

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

1.  Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.

Authors:  Lee J Martin; Yan Pan; Ann C Price; Wanda Sterling; Neal G Copeland; Nancy A Jenkins; Donald L Price; Michael K Lee
Journal:  J Neurosci       Date:  2006-01-04       Impact factor: 6.167

2.  Commentary: alpha-synuclein interacts with SOD1 and promotes its oligomerization.

Authors:  Anika M Helferich; Pamela J McLean; Jochen H Weishaupt; Karin M Danzer
Journal:  J Neurol Neuromedicine       Date:  2016

3.  Brain beta-amyloid accumulation in transgenic mice expressing mutant superoxide dismutase 1.

Authors:  Bradley J Turner; Qiao-Xin Li; Katrina M Laughton; Colin L Masters; Elizabeth C Lopes; Julie D Atkin; Surindar S Cheema
Journal:  Neurochem Res       Date:  2004-12       Impact factor: 3.996

4.  Accumulation of α-synuclein triggered by presynaptic dysfunction.

Authors:  Yasuto Nakata; Toru Yasuda; Masahiro Fukaya; Saori Yamamori; Makoto Itakura; Tomoko Nihira; Hideki Hayakawa; Aya Kawanami; Masakazu Kataoka; Makiko Nagai; Hiroyuki Sakagami; Masami Takahashi; Yoshikuni Mizuno; Hideki Mochizuki
Journal:  J Neurosci       Date:  2012-11-28       Impact factor: 6.167

Review 5.  Synucleinopathy in Amyotrophic Lateral Sclerosis: A Potential Avenue for Antisense Therapeutics?

Authors:  Bradley Roberts; Frances Theunissen; Francis L Mastaglia; P Anthony Akkari; Loren L Flynn
Journal:  Int J Mol Sci       Date:  2022-08-19       Impact factor: 6.208

6.  Comparison of alpha-synuclein immunoreactivity in the spinal cord between the adult and aged beagle dog.

Authors:  Ji-Hyeon Ahn; Jung-Hoon Choi; Joon-Ha Park; Bing-Chun Yan; In-Hye Kim; Jae-Chul Lee; Dae-Hwan Lee; Jin-Sang Kim; Hyung-Cheul Shin; Moo-Ho Won
Journal:  Lab Anim Res       Date:  2012-09-26

7.  α -Synuclein Modification in an ALS Animal Model.

Authors:  Eun Jin Yang; Sun-Mi Choi
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-12       Impact factor: 2.629

8.  α-synuclein interacts with SOD1 and promotes its oligomerization.

Authors:  Anika M Helferich; Wolfgang P Ruf; Veselin Grozdanov; Axel Freischmidt; Marisa S Feiler; Lisa Zondler; Albert C Ludolph; Pamela J McLean; Jochen H Weishaupt; Karin M Danzer
Journal:  Mol Neurodegener       Date:  2015-12-08       Impact factor: 14.195

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.